TITLE

FDA Actions

AUTHOR(S)
Elliott, William T.
PUB. DATE
April 2009
SOURCE
Travel Medicine Advisor;Apr2009 Pharmacology Watch, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents an update on regulatory actions taken by the U.S. Food and Drug Administration as of April 2, 2009. A public health advisory was issued by FDA concerning the risk of progressive multifocal leukoencephalopathy (PML) resulting from use of efalizumab for the treatment of psoriasis. The agency has reaffirmed its stand on cholesterol-lowering drugs in response to the results of a trial on simvastatin.
ACCESSION #
37198929

 

Related Articles

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Apr2009 Pharmacology, p2 

    This section offers news briefs on the regulatory measures made by the U.S. Food and Drug Administration (FDA) as of April 2009. A public health advisory was issued by concerning the risk of progressive multifocal leukoencephalopathy (PML) associated with the use of efalizumab for the treatment...

  • FDA Actions.  // Primary Care Reports;Apr2009 Pharmacology Watch, p2 

    The article reports on a public health advisory regarding the risk of progressive multifocal leukoencephalopathy (PML) issued by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis. Health care professionals were recommended by the FDA to monitor patients on efalizumab, as...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Apr2009 Supplement, p2 

    This section offers news briefs concerning pharmaceutical policies in the U.S. as of April 3, 2009. The U.S. Food & Drug Administration (FDA) has issued a public health advisory regarding the risk of progressive multifocal leukoencephalopathy (PML) associated with the use of efalizumab for the...

  • Drugs versus fooods, plus futility. Dickinson, James G. // Medical Marketing & Media;Apr98, Vol. 33 Issue 4, p10 

    Comments on the dispute whether Cholestin a potent cholesterol-lowering agent, is a natural food supplement or a drug which should be restricted by the United States (U.S.) Food and Drug Administration (FDA). Views of Merck and Company on the issue; Information on the product; Reference to the...

  • RARE BRAIN INFECTION CONFIRMED IN PATIENTS ON EFALIZUMAB.  // Dermatology Times;Mar2009, Vol. 30 Issue 3, p32 

    The article offers information on a public health advisory issued by the U.S. Food and Drug Administration (FDA) on February 19, 2009 which revealed three cases of progressive multifocal leukoencephalopathy (PML) in patients taking the psoriasis drug efalizumab (Raptiva). According to FDA, a...

  • NEWS brief.  // Dermatology Times;Mar2009, Vol. 30 Issue 3, p34 

    This section offers news briefs related to health and medicine as of March 2009. A public health advisory has been issued by the U.S. Food and Drug Administration (FDA) for the psoriasis drug Raptiva (efalizumab) from Genentech. A device is being developed for skin cancer detection without a...

  • Court Conquest for Cholestin; New Research Bolsters Evidence of Benefits.  // Environmental Nutrition;Apr99, Vol. 22 Issue 4, p3 

    Reports that a federal judge has ruled that the United States Food and Drug Administration (FDA) acted illegally in trying to stop sales of the cholesterol-lowering Cholestin. FDA's ban in the import of the drug's main ingredient, red yeast rice powder from China; Recommended levels of...

  • Antidote. Siegel, Marc // Medical Marketing & Media;Apr2012, Vol. 47 Issue 4, p12 

    The article presents the author's view on the warning placed by the U.S. Food & Drug Administration (FDA) on the risk of diabetes and cognitive problems on top cholesterol-lowering drugs.

  • NEW INDICATIONS.  // Drug Topics;5/19/2003, Vol. 147 Issue 10, p68 

    Reports that Merck & Co. has gained approval from the U.S. Food and Drug Administration for a change in its prescribing information for 40-mg Zocor, a cholesterol-lowering drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics